iiinova — where your digital self keeps evolving

Chris Hill @dochill1982.bsky.social · 27/09/2026

Nice study and the big ticket result for me is the effects on eGFR slope of Sibeprenlimab compared to others. Would be interesting to add in dual inhibitors like Atacicept for comparison!

000

Chris Hill @dochill1982.bsky.social · 19/09/2026

Much more commonly prescribed by critical care in UK

010

Reposted by Chris Hill

NEJM.org @nejm.org · 31/08/2026

Catheter-directed thrombolysis led to a lower risk of death, recurrent pulmonary embolism, or cardiorespiratory decompensation or collapse at 7 days than anticoagulation alone in intermediate-high–risk acute pulmonary embolism. Full PRAGUE-26 trial results: nej.md/4wyGCwb #ESCCongress

A table comparing primary outcomes of thrombolysis and standard care (death from any cause, recurrence of pulmonary embolism, or cardiorespiratory decompensation or collapse). A primary-outcome event occurred in 2
patients (0.7%) in the thrombolysis group and in 19 patients (6.8%) in the standard-care group. The relative risk was 0.10 (95% CI: 0.02–0.44).

022

Reposted by Chris Hill

NEJM.org @nejm.org · 27/08/2026

A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained through 14 months support β-cell function and a lack of immune response against the allograft. Full study results: nej.md/4wW5wGB

A graph showing the circulating C-peptide concentrations before and after transplantation and corresponding glucose management indicator (GMI) values (with each GMI calculated on the basis of the average glucose level over a period of 14 days).

022

Chris Hill @dochill1982.bsky.social · 13/08/2026

(Very) makeshift pinhole camera used to view the eclipse last night #dontgiveupthedayjob Remarkably it did actually work!

010

Reposted by Chris Hill

Arkana Labs @arkanalabs.bsky.social · 12/08/2026

Here is today’s #eyeSCANdy! Acellular scanning EM showing "craters" at high power on the subepithelial aspect of the glomerular basement membranes from a biopsy with membranous glomerulonephritis. Photo courtesy of Dr. Stephen Bonsib. #renal #pathology #kidneypath

023

Reposted by Chris Hill

NEJM.org @nejm.org · 09/08/2026

In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months. Full FIND-CKD trial results and Research Summary: nej.md/4wWOFV4

This image contains an excerpt from the Research Summary "Finerenone in Persons with Chronic Kidney Disease without Diabetes" published in the New England Journal of Medicine. It includes a diagram showing CKD without diabetes and participant statistics: 1,584 adults, average age 55, with 66% men and 34% women. Below are illustrations of finerenone and placebo pill bottles, each accompanied by participant numbers: N=793 for the former, and N=791 for the latter. A prompt to read the full Research Summary at NEJM.org sits at the bottom.

1111

Chris Hill @dochill1982.bsky.social · 10/06/2026

Another great trial from #CCR26 presented in Belfast - carbocisteine and hypertonic saline cause harm in ventilated patients

001

Chris Hill @dochill1982.bsky.social · 10/06/2026

Clinically v relevant results presented at #CCR26 in Belfast. Oseltamivir *worsens* outcome in ICU patients with Influenza!

021

Chris Hill @dochill1982.bsky.social · 07/06/2026

Also I take the point about the Obi v Ritux trial needing to be big to show difference but maybe nephrology needs to be braver. Yes it would be hard and expensive but many other specialties have been doing these head to head marginal gain trials for years e.g. haem, onc, cardiology

131

Chris Hill @dochill1982.bsky.social · 07/06/2026

Disappointing that, while FDA has made big strides over last 5 years in licensing for kidney disease, this kind of playing of the system is required. My wife is a hepatologist and is still astounded by the Terlipressin situation in US when in UK we have been giving on ward for years.

121

Chris Hill @dochill1982.bsky.social · 06/06/2026

If this was the plan why would an Obi v Ritux trial not have achieved the same outcome?

100

Chris Hill @dochill1982.bsky.social · 05/06/2026

This is good but what we really want is an Obi v Ritux trial

010

Chris Hill @dochill1982.bsky.social · 22/05/2026

Training programme in UK hasn’t been called nephrology for ages - it’s “Renal Medicine”.

111

Reposted by Chris Hill

kireports.bsky.social @kireports.bsky.social · 22/05/2026

Clinical Equipoise and Unimproved Outcomes following Posttransplant Cutaneous Squamous Cell Carcinoma #VisualAbstract by Krithika Mohan www.kireports.org/article/S2468-024… @bottomleymatt

001

Chris Hill @dochill1982.bsky.social · 16/05/2026

Excited for @kidneyboy.bsky.social to start his talk at Irish Nephrology Society!

100

Chris Hill @dochill1982.bsky.social · 09/05/2026

Always believed it’s anti-inflammatory action of the steroids that does the heavy lifting in stopping the haemorrhage

000

Chris Hill @dochill1982.bsky.social · 09/05/2026

Never been convinced by PLEX. PEXIVAS really only showed small benefit at 12 months at the expense of big additional risk. Mechanistically even in pulm haemorrhage it has never made sense to me - we’re doing a treatment that effectively anti coagulates someone who is bleeding??

110

Reposted by Chris Hill

American Journal of Kidney Diseases @ajkd.bsky.social · 28/04/2026

The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy bit.ly/4rzPtLO

021

Reposted by Chris Hill

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 21/04/2026

Another e-alert failure in Kidney International this time www.kidney-international.org/article/S008... With commentaries: - www.kidney-international.org/article/S008... - www.kidney-international.org/article/S008...

243

Chris Hill @dochill1982.bsky.social · 15/04/2026

Just made someone very overtly diabetic within 6 weeks of starting… Definitely not a “benign” steroid!

011

Chris Hill @dochill1982.bsky.social · 02/04/2026

How has BK beat CMV??? Scandalous! 😂

000

Chris Hill @dochill1982.bsky.social · 28/03/2026

Definitely because it’s a pain in someone who is proteinuric but also has HF - you can never get to the max possible dose of valsartan with the combination which is what I really want in those folks.

140

Chris Hill @dochill1982.bsky.social · 28/03/2026

True… Though could be done if funded from government agencies/charities etc. As for voclosporin - used it once and never again! Product info mandates monthly bloods for entire time they’re on it. Cheap as chips generic Tac all the way for me 😀

010

Chris Hill @dochill1982.bsky.social · 28/03/2026

A head to head comparison between Obi and Ritux would be v helpful. Theoretically Obi should give better B cell clearance and more durable response- might be like in lupus, why bother with Ritux when Obi works better?

242

Reposted by Chris Hill

American Journal of Kidney Diseases @ajkd.bsky.social · 10/03/2026

The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy bit.ly/4rs0u1r

011

Chris Hill @dochill1982.bsky.social · 06/03/2026

@askrenal.bsky.social anyone in England/Scotland/Wales - do you have to dispense Kinpeygo and Sparsentan direct from hospital pharmacy or is it available via community pharmacy? In NI we have to dispense direct from hospital due to an issue about cost parity in primary care.

000

Chris Hill @dochill1982.bsky.social · 03/03/2026

Looking forward to our March teaching session for neph trainees in NI! It’s all about the #NephMadness!

031

Reposted by Chris Hill

JAMA @jama.com · 03/03/2026

IgA nephropathy is the most common cause of immune-mediated glomerular disease worldwide. 📄 This Review summarizes the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy in adults. ja.ma/47bIhht

Illustration of IgA Nephropathy pathophysiology from JAMA. Four-hit hypothesis shows: 1) Aberrant IgA1 production; 2) Gd-IgA1 entering circulation; 3) Immune complex formation; 4) Complex deposition in glomerulus. Published online January 26, 2026.

054

Chris Hill @dochill1982.bsky.social · 25/02/2026

No uptake of HIF-PHIs in our unit either. Pricey when compared to ESA and no obvious benefits.

000

Reposted by Chris Hill

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 24/02/2026

This week we discuss the 2026 KDIGO anemia guidelines on #NephJC Read our deep dive into the data here www.nephjc.com/news/kdigo-a...

nephjc.com

2026 KDIGO Anemia Management Guidelines — NephJC

This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease

193

Chris Hill @dochill1982.bsky.social · 21/02/2026

Our unit has been routinely doing HDF for a number of years now. Great to see accumulating evidence of benefit. One practical point we learned though… Our unit was designed in 1990s for HD. The drains didn’t cope well with the turbid effluent from HDF so the place stank until we got them fixed!

031

Reposted by Chris Hill

Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 21/02/2026

Real-World Hospitalization Outcomes with On-Line Hemodiafiltration Versus High-Flux Hemodialysis ca. 2025 from @asnpublications.bsky.social #Nephpearls #NephSky #VisualAbstract by @husamjz.bsky.social 👉 pubmed.ncbi.nlm.nih.gov/41433104/

144

Chris Hill @dochill1982.bsky.social · 20/02/2026

I’m not on ASN communities but will try to sign up. Still think it would be a big shame to lose discussion on Bluesky - I really like it as a platform and think nephJC still works well on it.

020

Chris Hill @dochill1982.bsky.social · 20/02/2026

Maybe folks just became disillusioned with social media and afraid to post in case they get piled on? If so, that won’t change no matter what the platform.

131

Chris Hill @dochill1982.bsky.social · 20/02/2026

Thanks - has bone marrow/splenic involvement too so low WCC chronically making Aza a no-go. Saw @kidneyboy.bsky.social’s post about lack of discussion. Wonder if it’s nothing to do with platform but that attitudes to social media have changed after twitter became a s**tshow?

111

Chris Hill @dochill1982.bsky.social · 20/02/2026

#askrenal @nephjc.bsky.social have a young male with multisystem sarcoid. Eyes, liver, hilar LNs and interstitial nephritis. Granulomas so big you could pick them out without magnification on histo slide! Any experience of anti TNF as steroid sparing for renal involvement?

122

Reposted by Chris Hill

American Journal of Kidney Diseases @ajkd.bsky.social · 05/02/2026

Exercise and Kidney Health: Core Curriculum 2026 bit.ly/3YK6uXv (OPEN ACCESS)

034

Reposted by Chris Hill

kireports.bsky.social @kireports.bsky.social · 23/01/2026

Systematic Review of Efficacy and Safety of #Avacopan in #RealWorld Clinical Practice #VisualAbstract by @Cteodosiu www.kireports.org/article/S2468-024…

011

Reposted by Chris Hill

Lupus UK @lupusuk.bsky.social · 22/01/2026

NICE have recommended that a new treatment, obinutuzumab, can be used in combination with mycophenolate mofetil (MMF) to treat some patients with lupus nephritis in the NHS in England and Wales. 👉 Learn more at lupusuk.org.uk/latest-news #Lupus #LupusNephritis #Obinutuzumab

022

Reposted by Chris Hill

NEJM.org @nejm.org · 10/01/2026

PISCES trial: More than two thirds of patients receiving hemodialysis for end-stage kidney disease are affected by cardiovascular disease. Research findings on fish-oil supplementation in patients treated with hemodialysis are summarized in a new Quick Take video. nej.md/3YsyWx2 #MedSky

A visual representation of the PISCES trial, which assessed whether fish oil could prevent cardiovascular events in patients on hemodialysis.

071

Chris Hill @dochill1982.bsky.social · 05/01/2026

View from the office this morning. Sunrise over #Belfast

010

Reposted by Chris Hill

American Journal of Kidney Diseases @ajkd.bsky.social · 29/11/2025

Quantifying APOL1, Human Leukocyte Antigen, and Other Genetic Contributions to Unexplained Kidney Failure #OpenAccess bit.ly/4nfGoXe

Breakdown of solved cases by gene category. Breakdown of the solved uKF cases by gene and phenotypic category. All percentages represent a proportion of the total solved cases (n=38). ADTKD, autosomal dominant tubulointerstitial kidney disease; CAKUT, congenital anomalies of the kidneys and urinary tract.

031